Literature DB >> 21734236

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

Samantha Solito1, Erika Falisi, Claudia Marcela Diaz-Montero, Andrea Doni, Laura Pinton, Antonio Rosato, Samuela Francescato, Giuseppe Basso, Paola Zanovello, Georgiana Onicescu, Elizabeth Garrett-Mayer, Alberto J Montero, Vincenzo Bronte, Susanna Mandruzzato.   

Abstract

We recently demonstrated that human BM cells can be treated in vitro with defined growth factors to induce the rapid generation of myeloid-derived suppressor cells (MDSCs), hereafter defined as BM-MDSCs. Indeed, combination of G-CSF + GM-CSF led to the development of a heterogeneous mixture of immature myeloid cells ranging from myeloblasts to band cells that were able to suppress alloantigen- and mitogen-stimulated T lymphocytes. Here, we further investigate the mechanism of suppression and define the cell subset that is fully responsible for BM-MDSC-mediated immune suppression. This population, which displays the structure and markers of promyelocytes, is however distinct from physiologic promyelocytes that, instead, are devoid of immuosuppressive function. In addition, we demonstrate that promyelocyte-like cells proliferate in the presence of activated lymphocytes and that, when these cells exert suppressive activity, they do not differentiate but rather maintain their immature phenotype. Finally, we show that promyelocyte-like BM-MDSCs are equivalent to MDSCs present in the blood of patients with breast cancer and patients with colorectal cancer and that increased circulating levels of these immunosuppressive myeloid cells correlate with worse prognosis and radiographic progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734236      PMCID: PMC3709641          DOI: 10.1182/blood-2010-12-325753

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion.

Authors:  Anne-Sophie Dugast; Thomas Haudebourg; Flora Coulon; Michèle Heslan; Fabienne Haspot; Nicolas Poirier; Romain Vuillefroy de Silly; Claire Usal; Helga Smit; Bernard Martinet; Pamela Thebault; Karine Renaudin; Bernard Vanhove
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

2.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.

Authors:  Massimo Cristofanilli; Daniel F Hayes; G Thomas Budd; Mathew J Ellis; Alison Stopeck; James M Reuben; Gerald V Doyle; Jeri Matera; W Jeffrey Allard; M Craig Miller; Herbert A Fritsche; Gabriel N Hortobagyi; Leon W M M Terstappen
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

3.  Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.

Authors:  Massimo Cristofanilli; Kristine R Broglio; Valentina Guarneri; Summer Jackson; Herbert A Fritsche; Rabiul Islam; Shaheenah Dawood; James M Reuben; Shu-Wan Kau; Juanita M Lara; Saviti Krishnamurthy; Naoto T Ueno; Gabriel N Hortobagyi; Vincente Valero
Journal:  Clin Breast Cancer       Date:  2007-02       Impact factor: 3.225

4.  Products of anti-CD3/anti-CD28 activated lymphocytes induce differentiation and maturation of dendritic cells and have adjuvant-like activity in vitro and in vivo.

Authors:  Kristina M Harris; Petra Lenz; Kim G Hankey; Thomas MacVittie; Ann Farese; Kaori Nakajima; Kenichiro Hasumi; Dean L Mann
Journal:  Clin Immunol       Date:  2008-08-08       Impact factor: 3.969

Review 5.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.

Authors:  Paulo C Rodríguez; Augusto C Ochoa
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 6.  Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.

Authors:  Ilaria Marigo; Luigi Dolcetti; Paolo Serafini; Paola Zanovello; Vincenzo Bronte
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

7.  Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression.

Authors:  Heriberto Prado-Garcia; Dolores Aguilar-Cazares; Manuel Meneses-Flores; Jorge Morales-Fuentes; Jose Sullivan Lopez-Gonzalez
Journal:  Cancer Immunol Immunother       Date:  2007-08-01       Impact factor: 6.968

8.  Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways.

Authors:  Dong-Ming Kuang; Qiyi Zhao; Jing Xu; Jing-Ping Yun; Changyou Wu; Limin Zheng
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

9.  Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity.

Authors:  Markus Munder; Faustino Mollinedo; Jero Calafat; Javier Canchado; Cristina Gil-Lamaignere; José M Fuentes; Claudia Luckner; Gwendolyn Doschko; Germán Soler; Klaus Eichmann; Frank-Michael Müller; Anthony D Ho; Martin Goerner; Manuel Modolell
Journal:  Blood       Date:  2004-11-16       Impact factor: 22.113

10.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.

Authors:  Silvia Deaglio; Karen M Dwyer; Wenda Gao; David Friedman; Anny Usheva; Anna Erat; Jiang-Fan Chen; Keiichii Enjyoji; Joel Linden; Mohamed Oukka; Vijay K Kuchroo; Terry B Strom; Simon C Robson
Journal:  J Exp Med       Date:  2007-05-14       Impact factor: 14.307

View more
  153 in total

Review 1.  Myeloid-derived suppressor cells in transplantation and cancer.

Authors:  Jordi C Ochando; Shu Hsia Chen
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

2.  TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis.

Authors:  Liliana Guedez; Sandra Jensen-Taubman; Dimitra Bourboulia; Clifford J Kwityn; Beiyang Wei; John Caterina; William G Stetler-Stevenson
Journal:  J Immunother       Date:  2012-07       Impact factor: 4.456

Review 3.  Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Semin Cancer Biol       Date:  2012-01-31       Impact factor: 15.707

4.  Regulation of immunopathology in hepatitis B virus infection.

Authors:  Silvia Piconese; Vincenzo Barnaba
Journal:  Nat Med       Date:  2015-06       Impact factor: 53.440

Review 5.  Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Authors:  Audry Fernández; Liliana Oliver; Rydell Alvarez; Luis E Fernández; Kelvin P Lee; Circe Mesa
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.

Authors:  Cristina Iclozan; Scott Antonia; Alberto Chiappori; Dung-Tsa Chen; Dmitry Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2013-04-16       Impact factor: 6.968

7.  STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.

Authors:  David Vasquez-Dunddel; Fan Pan; Qi Zeng; Mikhail Gorbounov; Emilia Albesiano; Juan Fu; Richard L Blosser; Ada J Tam; Tullia Bruno; Hao Zhang; Drew Pardoll; Young Kim
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

Review 8.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

Review 9.  Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies.

Authors:  Peng-Fei Wang; Si-Ying Song; Ting-Jian Wang; Wen-Jun Ji; Shou-Wei Li; Ning Liu; Chang-Xiang Yan
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

10.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.

Authors:  Steffen Walter; Toni Weinschenk; Arnulf Stenzl; Romuald Zdrojowy; Anna Pluzanska; Cezary Szczylik; Michael Staehler; Wolfram Brugger; Pierre-Yves Dietrich; Regina Mendrzyk; Norbert Hilf; Oliver Schoor; Jens Fritsche; Andrea Mahr; Dominik Maurer; Verona Vass; Claudia Trautwein; Peter Lewandrowski; Christian Flohr; Heike Pohla; Janusz J Stanczak; Vincenzo Bronte; Susanna Mandruzzato; Tilo Biedermann; Graham Pawelec; Evelyna Derhovanessian; Hisakazu Yamagishi; Tsuneharu Miki; Fumiya Hongo; Natsuki Takaha; Kosei Hirakawa; Hiroaki Tanaka; Stefan Stevanovic; Jürgen Frisch; Andrea Mayer-Mokler; Alexandra Kirner; Hans-Georg Rammensee; Carsten Reinhardt; Harpreet Singh-Jasuja
Journal:  Nat Med       Date:  2012-07-29       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.